Akeso (SZSC:9926) - 주가, 뉴스 및 분석

9926 주식 개요

바이오 제약 회사인 Akeso는 항체 의약품을 연구, 개발, 제조 및 상용화하는 회사입니다. 자세한 내용

9926 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	6/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 41.1% 에서 거래

수익은 매년 53.48% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

Akeso, Inc. 경쟁사

Innovent Biologics

SEHK:1801

HK$60.8b

Ascentage Pharma Group International

SEHK:6855

HK$13.2b

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$38.4b

Shanghai Henlius Biotech

SEHK:2696

HK$11.4b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Akeso
과거 주가
현재 주가	HK$76.80
52주 최고치	HK$77.65
52주 최저치	HK$26.45
베타	0.56
11개월 변경	10.50%
3개월 변경 사항	64.81%
1년 변경 사항	60.50%
33년 변화	53.91%
5년 변화	n/a
IPO 이후 변화	103.44%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	9926	HK Biotechs	HK 마켓
7D	20.2%	5.5%	-2.1%
1Y	60.5%	-12.8%	9.7%

수익률 대 산업: 9926 지난 1년 동안 -12.8 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 9926 지난 1년 동안 9.7 %를 반환한 Hong Kong 시장을 초과했습니다.

가격 변동성

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement	11.0%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.1%
10% least volatile stocks in HK Market	4.3%

안정적인 주가: 9926 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 9926 의 주간 변동성( 11% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2012	2,815	Michelle Xia	www.akesobio.com

바이오 제약 회사인 아케소는 항체 의약품을 연구, 개발, 제조 및 상용화하는 회사입니다. 회사는 자궁경부암, 위암(GC), 위식도 접합부(GEJ) 암, 상피내암(ESCC), 간세포암(HCC), 소세포폐암(SCLC), 비소세포폐암(NSCLC), 췌장암 및 고형 종양 치료를 위한 PD-1/CTLA-4 이중 특이 항체인 AK104를 개발하고 있습니다; 비소세포폐암, 삼중음성유방암(TNBC), 두경부암, 간세포암, 대장암 및 난소암, 고형암 치료를 위한 PD-1/VEGF 이중특이항체 AK112를 개발 중입니다. 또한 골수형성이상증후군, 급성골수성백혈병, 위암, 전이성 위장관기질종양, 전이성 비소세포폐암, 비소세포폐암, 급성골수성백혈병, 고형암/림프종 치료를 위한 CD47 단일클론 항체 AK117을 개발 중입니다; 전형적인 호지킨 림프종(R/R cHL), 비소세포폐암, 비소세포폐암, 간세포암, 비소세포폐암, 갑상선암, 중피종 및 흉선암, ESCC, UC, GC, GEJ, 담관암, 신경내분비종양 및 불일치 복구 결핍 고형 종양 치료를 위한 PD-1 단일클론 항체인 AK105; 고형암 및 비소세포폐암 치료를 위한 CD73 단일클론항체 AK119, 위암, 간세포암, 간세포암 및 고형암 치료를 위한 VEGFR-2 단일클론항체 AK109.

Akeso, Inc. 기본 사항 요약

Akeso 의 수익과 매출은 시가총액과 어떻게 비교하나요?
9926 기본 통계
시가총액	HK$68.93b
수익(TTM)	-HK$789.83m
수익(TTM)	HK$2.01b

34.2x

P/S 비율

-87.3x

P/E 비율

9926 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
9926 손익 계산서(TTM)
수익	CN¥1.87b
수익 비용	CN¥146.05m
총 이익	CN¥1.73b
기타 비용	CN¥2.46b
수익	-CN¥735.33m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.82
총 마진	92.21%
순이익 마진	-39.24%
부채/자본 비율	64.2%

9926 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

9926 주식 개요

보상

위험 분석

Akeso, Inc. 경쟁사

SEHK:1801

HK$60.8b

SEHK:6855

HK$13.2b

SEHK:6990

HK$38.4b

SEHK:2696

HK$11.4b

가격 내역 및 성능

최근 뉴스 및 업데이트

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Recent updates

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven